CAMBRIDGE, Mass., Nov. 15,
2022 /PRNewswire/ -- Omega Therapeutics, Inc.
(Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company
pioneering the first systematic approach to use mRNA therapeutics
as a new class of programmable epigenetic medicines, today
announced that it has been named among BioSpace's Best Places to
Work 2023 report in the small employers category.
"We are honored and humbled to be recognized for the culture we
have built that unites our core values and prioritizes innovation,
leadership and collaboration among Omegans," said Mahesh Karande, President and Chief Executive
Officer of Omega Therapeutics. "The pioneering spirit of our
employees is reflected in our work to harness the full power of
epigenetics and advance novel mRNA therapies in service of
patients. We could not be prouder to see how the company has grown
and evolved and will always endeavor to live up to our ethos,
'ambitious, yet humble' and the values that have guided us here.
We'd like to thank our team for their continued passion and
dedication as well as the biopharma community for recognizing the
culture that Omegans have worked hard to foster, maintain, and grow
together."
BioSpace's Best Places to Work 2023 was determined by input from
company employees as well as voting from more than 2,000 life
sciences professionals. Areas for consideration included
innovation, compensation, career growth opportunities, leadership,
culture, diversity, equity and inclusion, reputation, flexibility
and remote work. To view the complete lists of 2023 Best Places to
Work, click here.
About Omega
Therapeutics
Omega Therapeutics, founded by Flagship Pioneering, is a
clinical-stage biotechnology company pioneering the first
systematic approach to use mRNA therapeutics as a new class of
programmable epigenetic medicines. The Company's OMEGA Epigenomic
Programming™ platform harnesses the power of epigenetics, the
mechanism that controls gene expression and every aspect of an
organism's life from cell genesis, growth, and differentiation to
cell death. Using a suite of technologies, paired with Omega's
process of systematic, rational, and integrative drug design, the
OMEGA platform enables control of fundamental epigenetic processes
to correct the root cause of disease by returning aberrant gene
expression to a normal range without altering native nucleic acid
sequences. Omega's modular and programmable mRNA medicines, Omega
Epigenomic Controllers™, are designed to target specific epigenomic
loci within insulated genomic domains, EpiZips™, from amongst
thousands of unique, mapped, and validated genome-wide
DNA-sequences, with high specificity to durably tune single or
multiple genes to treat and cure diseases through Precision Genomic
Control™. Omega is currently advancing a broad pipeline of
development candidates spanning a range of disease areas, including
oncology, regenerative medicine, multigenic diseases including
immunology, and select monogenic diseases, including
alopecia.
For more information, visit omegatherapeutics.com, or
follow us on Twitter and LinkedIn.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the timing and design of our Phase 1/2
MYCHELANGELOTM I clinical trial; the potential of the
OMEGA platform to engineer programmable epigenetic mRNA
therapeutics that successfully regulate gene expression by
targeting insulated genomic domains; expectations surrounding the
potential of our product candidates, including OTX-2002 and
OTX-2101; and expectations regarding our pipeline, including trial
design, initiation of preclinical studies and advancement of
multiple preclinical development programs in oncology, immunology,
regenerative medicine, and select monogenic diseases. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, the following: the novel
technology on which our product candidates are based makes it
difficult to predict the time and cost of preclinical and clinical
development and subsequently obtaining regulatory approval, if at
all; the substantial development and regulatory risks associated
with epigenomic controller machines due to the novel and
unprecedented nature of this new category of medicines; our limited
operating history; the incurrence of significant losses and the
fact that we expect to continue to incur significant additional
losses for the foreseeable future; our need for substantial
additional financing; our investments in research and development
efforts that further enhance the OMEGA platform, and their impact
on our results; uncertainty regarding preclinical development,
especially for a new class of medicines such as epigenomic
controllers; potential delays in and unforeseen costs arising from
our clinical trials; the fact that our product candidates may be
associated with serious adverse events, undesirable side effects or
have other properties that could halt their regulatory development,
prevent their regulatory approval, limit their commercial
potential, or result in significant negative consequences; the
impact of increased demand for the manufacture of mRNA and LNP
based vaccines to treat COVID-19 on our development plans;
difficulties manufacturing the novel technology on which our OEC
candidates are based; our ability to adapt to rapid and significant
technological change; our reliance on third parties for the
manufacture of materials; our ability to successfully acquire and
establish our own manufacturing facilities and infrastructure; our
reliance on a limited number of suppliers for lipid excipients used
in our product candidates; our ability to advance our product
candidates to clinical development; and our ability to obtain,
maintain, enforce and adequately protect our intellectual property
rights. These and other important factors discussed under the
caption "Risk Factors" in our most recent Quarterly Report on Form
10-Q and our Annual Report on Form 10-K for the year ended
December 31, 2022, and our other
filings with the SEC, could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking statements
represent management's estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
Investor Contact:
Eva Stroynowski
617.949.4370
estroynowski@omegatx.com
Media Contact:
Jason
Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/omega-therapeutics-named-one-of-biospaces-2023-best-places-to-work-301677664.html
SOURCE Omega Therapeutics